Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

GUB014295

Stage Phase 1Stale

Sponsor AbbVie

Route injection

Sources

registry, as of 2026-01-15Stale

https://clinicaltrials.gov/study/NCT06144684

A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295. Overall status COMPLETED. Phases PHASE1. Lead sponsor AbbVie. Enrollment 76. Conditions Healthy Volunteers; Overweight. This is a two-part, single centre, double-blind (within cohorts), randomised, placebo-controlled, single (Part 1) and multiple (Part 2) ascending subcutaneous dose study in lean to overweight or obese but otherwise healthy men (Part 1) and men and non-pregnant, non-lactating wome

ClinicalTrials.gov NCT06144684 protocol and results modules

Studies

A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295

Registry NCT06144684

Phase Phase 1

Status Completed

Enrollment 76

Start 2023-11-29

Primary completion 2026-01-05

Study completion 2026-01-05

Catalyst Primary completion. 2026-01-05. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Placebo

Population Healthy Volunteers; Overweight

GUB014295

Comparator placebo

Population Healthy Volunteers; Overweight